Business
Pfizer to develop mRNA vaccines without BioNTech
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
Pfizer Inc (NYSE: PFE)‘s success in developing an effective COVID-19 vaccine in record time has given the pharmaceutical giant the confidence to invest heavily in the technology that underpins that vaccine. In an interview with The Wall Street Journal on Tuesday, CEO Albert Bourla revealed that Pfizer plans to become a leader in the development of new vaccines that rely on messenger RNA (mRNA).
Unfortunately for BioNTech (NASDAQ: BNTX), those plans don’t rely on a continuation of the collaboration agreement that brought the world its first authorized mRNA-based vaccine. According to Bourla, Pfizer doesn’t need to work with…
-
General13 hours agoFarmers develop ‘autofill’ tech so agricultural robots can operate around the clock
-
Noosa News19 hours agoRevealed: 75 Qld suburbs you could afford to buy in if lending standards drop
-
General16 hours agoTrump mulling whether to fire US Fed chair Powell
-
Noosa News19 hours agoNowhere is growing like this corner of Queensland. It’s changing the political game